Using advanced techniques to identify causes of uveitis
Programmable Phage Display Peptidomes to Characterize Uveitis
['FUNDING_R21'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10993534
This study is looking at how to better diagnose and treat uveitis, a serious eye condition that can cause vision loss, by using new technology to find specific markers in the eye fluids of patients, which could help doctors provide more accurate care.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10993534 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding uveitis, a group of eye diseases that can lead to blindness if not properly diagnosed and treated. The team will utilize innovative programmable phage display technology to identify specific autoantigens and antibodies in the eye fluids of patients suffering from anterior uveitis. By analyzing samples from patients with idiopathic and viral-associated uveitis, the researchers aim to discover new biomarkers that can improve diagnostic accuracy and treatment options. This approach combines high-throughput sequencing with advanced bioassays to enhance our understanding of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with anterior uveitis or have suspected viral-associated uveitis.
Not a fit: Patients with uveitis caused by known factors or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic methods for uveitis, ultimately reducing the risk of blindness for patients.
How similar studies have performed: While the use of phage display technology is well-established in other fields, its application in uveitis diagnostics is novel and has not been extensively tested.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DOAN, THUY A — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: DOAN, THUY A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.